Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 9:14 PM
Ignite Modification Date: 2025-12-25 @ 7:03 PM
NCT ID: NCT00995904
Description: All 25 subjects who received 21ug MAP0020, 24 subjects who received 42ug MAP0020, and 24 subjects who received 84ug MAP0020 are included in the adverse event analysis.
Frequency Threshold: 5
Time Frame: None
Study: NCT00995904
Study Brief: Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
21ug MAP0020 21ug of unit dose budesonide inhalation suspension delivered by AeronebĀ® Go (MAP0020) as per protocol None None 0 25 2 25 View
42ug MAP0020 42ug of unit dose budesonide inhalation suspension delivered by AeronebĀ® Go (MAP0020) as per protocol None None 0 24 1 24 View
84ug MAP0020 84ug of unit dose budesonide inhalation suspension delivered by AeronebĀ® Go (MAP0020) as per protocol None None 0 24 0 24 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Asthma SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA 12.0 View